Human Oncology & Pathogenesis Program

The Ingo Mellinghoff Lab

Share
Print
Back to Top

Research

Ingo K. Mellinghoff, MD, FACP

Our laboratory focuses on the study of molecular pathways that regulate brain tumor growth. Our long-term goal is to develop therapeutic paradigms that target specific properties of primary brain tumors, including genetic alterations in cancer signaling pathways, unique aspects of brain tumor metabolism, or interactions of brain tumor cells with their brain microenvironment. Our studies in experimental brain tumor models are closely linked to the evaluation of novel agents in early-phase clinical trials.

The Ingo Mellinghoff Lab

Featured News

Ingo Mellinghoff, Chair of the Department of Neurology at Memorial Sloan Kettering
Brain Trust: 8 Questions with Ingo Mellinghoff

Ingo Mellinghoff is optimistic about the future of brain cancer treatments as the new Chair of MSK’s Department of Neurology.
Pictured: Ingo Mellinghoff
Ingo Mellinghoff Named the Evnin Family Chair in Neuro-Oncology

Physician-scientist Ingo Mellinghoff has been designated the incumbent of the Evnin Family Chair in Neuro-Oncology. Established through the generosity ...
Announcement
Pictured: American Association of Cancer Research Annual Meeting 2012
Memorial Sloan Kettering Discoveries in Personalized Medicine Highlighted at Major Cancer Research Meeting; Investigators Honored

The American Association for Cancer Research (AACR), the world's oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.

View All Featured News

Publications

Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweek R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ. Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunol Res. 2022 Mar 1;10(3):303-313. doi: 10.1158/2326-6066.CIR-21-1083.

Tang CP, Clark O, Ferrarone JR, Campos C, Lalani AS, Chodera JD, Intlekofer AM, Elemento O, Mellinghoff IK. GCN2 kinase activation by ATP-competitive kinase inhibitors. Nat Chem Biol. 2022 Feb;18(2):207-215. doi: 10.1038/s41589-021-00947-8. Epub 2021 Dec 23.

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15. 

Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK. Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight. 2016 May 5;1(6):e87030. doi: 10.1172/jci.insight.87030.

View All Publications

People

Pictured: Ingo Mellinghoff

Ingo K. Mellinghoff, MD, FACP

  • Physician-scientist Ingo Mellinghoff studies signal transduction alterations in primary brain tumors.
  • MD, Technical University Munich (Germany)
646-888-2766
Office Phone
View physician profile
Physician profile

Members

Carl Campos
Carl Campos

Lab Manager

Christian Grommes, MD
Christian Grommes

Associate Attending

Maya Graham
Maya Graham

Instructor

Alexandra Miller
Alexandra Miller

Assistant Attending

Daniel Navarrete
Daniel Navarrete

Senior Research Assistant

Smrutiben Mehta
Smrutiben Mehta

Research Assistant

Charli Hertz
Charli Hertz

Research Technician

Brian Greenstein

Research Technician 

Maryam Pourmaleki
Maryam Pourmaleki

Graduate Student

Ariana Izawa-Ishiguro

Graduate Student

Lab Alumni
Owen Clark
Owen Clark

Senior Research Scientist

Alex Lee
Alex Lee

Research Technician

Veronica Nagle
Veronica Nagle

Graduate Student

Colin Tang
Colin Tang

Graduate Student

Sarah Tang
Sarah Tang
Lab Affiliations

Achievements

  • Member, Association of American Physicians (2020)
  • Member, American Society of Clinical Investigation (2013)
  • Advanced Clinical Research Award, American Society of Clinical Oncology (2009)
  • Clinical Scientist Development Award, Doris Duke Charitable Foundation (2008)
  • Translational Science Award, Sidney Kimmel Foundation (2008)
Read more
  • Distinguished Scientist, Sontag Foundation (2007)
  • Scholar, Forbeck Research Foundation (2005)
  • Young Investigator Award, American Society of Clinical Oncology (2003)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ingo K. Mellinghoff discloses the following relationships and financial interests:

  • Agios Pharmaceuticals
    Provision of Services
  • American Society of Clinical Oncology (ASCO)
    Provision of Services
  • AstraZeneca
    Provision of Services (uncompensated)
  • Cardinal Health
    Provision of Services
  • DC Europa Limited
    Provision of Services (uncompensated)
  • Doris Duke Charitable Foundation
    Provision of Services
  • European Association of Neuro-Oncology (EANO)
    Provision of Services (uncompensated)
  • Hartford Healthcare
    Provision of Services
  • MD Anderson
    Provision of Services
  • Novartis
    Provision of Services
  • Roche
    Provision of Services
  • Voyager Therapeutics Inc.
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: